Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases [0.03%]
自身免疫性炎症疾病重度免疫抑制患者COVID-19暴露前抗SARS-CoV-2单克隆抗体疗法
Tiphaine Goulenok,Laure Delaval,Nicole Delory et al.
Tiphaine Goulenok et al.
Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study [0.03%]
阿巴西普治疗IgG4相关性疾病概念验证性研究：一项前瞻性、开放标签、单臂、单中心研究
Mark A Matza,Cory A Perugino,Liam Harvey et al.
Mark A Matza et al.
Background: There is strong rationale for interference with T cell co-stimulation in IgG4-related disease (IgG4-RD), but the literature to evaluate this is limited to a single case report. ...
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease [0.03%]
免疫介导性炎症性疾病患者的甲氨蝶呤和TNF抑制剂对COVID-19疫苗长期免疫原性的影响
Rebecca H Haberman,Seungha Um,Jordan E Axelrad et al.
Rebecca H Haberman et al.
Randy Q Cron
Randy Q Cron
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study [0.03%]
儿童多系统炎症综合征中针对IL-1受体拮抗剂的自身抗体：一项多中心回顾性队列研究
Jochen Pfeifer,Bernhard Thurner,Christoph Kessel et al.
Jochen Pfeifer et al.
Background: Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious complication of infection with SARS-CoV-2. A possible involvement of pathogenetically relevant autoantibodies has been discussed. Rec...
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases [0.03%]
风湿病和肌肉骨骼疾病患者第三针SARS-CoV-2疫苗接种后较差抗体反应的影响因素
Caoilfhionn M Connolly,Teresa Po-Yu Chiang,Mayan Teles et al.
Caoilfhionn M Connolly et al.
IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 [0.03%]
白细胞介素-1受体拮抗剂、MIS-C以及SARS-CoV-2的特异自身免疫反应
Hamid Bassiri,Scott W Canna
Hamid Bassiri
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial [0.03%]
鲁索利替尼联合标准治疗用于新冠肺炎住院患者的治疗：RUXCOVID随机、双盲、安慰剂对照、三期临床试验
MeiLan K Han,Martti Antila,Joachim H Ficker et al.
MeiLan K Han et al.
Background: COVID-19 is associated with acute respiratory distress and cytokine release syndrome. The Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib reduces inflammatory cytokine concentrations in disorders characterised ...
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies - Authors' reply [0.03%]
B细胞耗竭后接种SARS-CoV-2疫苗的细胞反应：研究结果不一致——作者回复
Matthias B Moor,Franziska Suter-Riniker,Cedric Hirzel et al.
Matthias B Moor et al.